Bayer announces positive topline results for NUBEQA (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC) Read more
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms Read more
CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab Read more
Merck Begins Commercial Production of First GMP-Compliant Manufacturing Line for Cell Culture Media in China Read more
Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics Read more
Rgenta Therapeutics Announces FDA Clearance of IND Application for RGT-61159, an Oral Small Molecule RNA Modulator Designed to Halt Disease-Driver MYB Production in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC) Read more
AusperBio Receives Breakthrough Therapy Designation for AHB-137 in Chronic Hepatitis B Treatment Read more